Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOBT NASDAQ:KROS NASDAQ:PHAT NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOBTIO Biotech$1.31+24.8%$1.66$0.66▼$2.48$119.24M0.44893,798 shs19.91 million shsKROSKeros Therapeutics$13.71+2.7%$14.00$9.12▼$72.37$556.90M1.33999,909 shs305,989 shsPHATPhathom Pharmaceuticals$10.38+1.0%$8.93$2.21▼$19.71$736.36M0.451.80 million shs1.04 million shsRLAYRelay Therapeutics$3.35+3.1%$3.47$1.77▼$10.72$577.57M1.622.32 million shs1.79 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOBTIO Biotech-41.99%-51.16%-28.57%+5.00%-25.53%KROSKeros Therapeutics-2.77%-8.69%-7.55%-0.89%-70.58%PHATPhathom Pharmaceuticals+5.54%+18.98%+11.98%+210.57%-12.51%RLAYRelay Therapeutics+0.93%-10.96%-9.72%+14.84%-51.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIOBTIO Biotech3.0144 of 5 stars3.73.00.00.02.22.50.6KROSKeros Therapeutics2.6622 of 5 stars3.32.00.00.02.23.30.6PHATPhathom Pharmaceuticals3.3159 of 5 stars3.52.00.00.02.35.00.6RLAYRelay Therapeutics2.0121 of 5 stars3.50.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOBTIO Biotech 3.33Buy$8.67561.58% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.00118.82% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5068.59% UpsideRLAYRelay Therapeutics 2.92Moderate Buy$17.25414.93% UpsideCurrent Analyst Ratings BreakdownLatest IOBT, PHAT, KROS, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025IOBTIO BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$6.00 ➝ $4.008/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $20.008/8/2025RLAYRelay TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $19.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.006/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.005/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.00(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AKROSKeros Therapeutics$3.55M156.87N/AN/A$14.11 per share0.97PHATPhathom Pharmaceuticals$55.25M13.33N/AN/A($3.71) per share-2.80RLAYRelay Therapeutics$10.01M57.70N/AN/A$4.65 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)KROSKeros Therapeutics-$187.35M$0.3144.23N/A1.808.06%2.96%2.74%N/APHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%N/ARLAYRelay Therapeutics-$337.71M-$1.95N/AN/AN/AN/A-41.49%-37.43%N/ALatest IOBT, PHAT, KROS, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025IOBTIO Biotech-$0.35N/AN/AN/AN/AN/A8/7/2025Q2 2025RLAYRelay Therapeutics-$0.49-$0.41+$0.08-$0.41$0.07 million$0.70 million8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIOBTIO BiotechN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOBTIO BiotechN/A2.322.32KROSKeros TherapeuticsN/A21.1121.11PHATPhathom PharmaceuticalsN/A2.382.35RLAYRelay TherapeuticsN/A20.9220.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOBTIO Biotech54.76%KROSKeros Therapeutics71.56%PHATPhathom Pharmaceuticals99.01%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipIOBTIO Biotech2.30%KROSKeros Therapeutics22.90%PHATPhathom Pharmaceuticals24.10%RLAYRelay Therapeutics4.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOBTIO Biotech30N/AN/ANot OptionableKROSKeros Therapeutics10040.62 million31.31 millionOptionablePHATPhathom Pharmaceuticals11070.94 million53.85 millionOptionableRLAYRelay Therapeutics330172.41 million164.96 millionOptionableIOBT, PHAT, KROS, and RLAY HeadlinesRecent News About These CompaniesRelay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?5 hours ago | zacks.comRelay Therapeutics (RLAY) Gets a Buy from Bank of America SecuritiesAugust 9 at 12:19 AM | theglobeandmail.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst DowngradeAugust 9 at 12:59 PM | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Price Target Lowered to $19.00 at Raymond James FinancialAugust 9 at 12:25 PM | marketbeat.comRelay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comRelay (RLAY) Q2 Loss Narrows 41%August 7, 2025 | fool.comRelay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate UpdatesAugust 7, 2025 | globenewswire.comRelay Therapeutics Q2 2025 Earnings PreviewAugust 7, 2025 | seekingalpha.comPreview: Relay Therapeutics's EarningsAugust 7, 2025 | benzinga.comRelay Therapeutics (NASDAQ:RLAY) Shares Up 8.2% - Here's What HappenedAugust 5, 2025 | marketbeat.comBarclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PTAugust 5, 2025 | msn.comRelay Therapeutics: What's Next For H2 2025?August 2, 2025 | seekingalpha.comBrokerages Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $17.67August 2, 2025 | americanbankingnews.comBarclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)August 1, 2025 | msn.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 4,069 Shares of StockJuly 31, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 15,724 SharesJuly 31, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 18,276 Shares of StockJuly 31, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 18,380 SharesJuly 31, 2025 | marketbeat.comDonald A. Bergstrom Sells 26,701 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockJuly 31, 2025 | marketbeat.comRelay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025July 31, 2025 | globenewswire.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $15,218.06 in StockJuly 31, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOBT, PHAT, KROS, and RLAY Company DescriptionsIO Biotech NASDAQ:IOBT$1.31 +0.26 (+24.76%) Closing price 04:00 PM EasternExtended Trading$1.32 +0.01 (+1.15%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Keros Therapeutics NASDAQ:KROS$13.71 +0.36 (+2.70%) Closing price 04:00 PM EasternExtended Trading$13.70 -0.01 (-0.04%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Phathom Pharmaceuticals NASDAQ:PHAT$10.38 +0.10 (+0.97%) Closing price 04:00 PM EasternExtended Trading$10.19 -0.19 (-1.83%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Relay Therapeutics NASDAQ:RLAY$3.35 +0.10 (+3.08%) Closing price 04:00 PM EasternExtended Trading$3.35 0.00 (-0.12%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces Alphabet Reclaims $200 Threshold—Bull Run Reignited? Apple & Trump: $100B Investment, Tariffs News Push Shares Up 13% How Vertiv Is Cashing in on AI's Power Crisis CrowdStrike Faces Valuation Test Before Key Earnings Report AMD Paves Path for Market Share Gains: Stock Rally Has Just Begun Post-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access